You searched for "therapeutics"
Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals
Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...The David J Apple International Laboratory for Ocular Pathology – a legacy of pioneering IOL research
David Apple and Gerd Auffarth. The Apple Lab at the David J Apple Center for Vision Research in Heidelberg is a thriving international laboratory for research into intraocular devices. The lab continues the work of David J Apple, a world-renowned...The paediatric cataract: an overview of the embryology and pathophysiology
In the first of the two articles (see Part 2 here) on paediatric cataracts, Samuel Aryee reviews the aetiology of this condition. Cataracts arise from opacification of the natural transparent lens, which can cause partial or total blindness. Although the...The future of multi-professional working in eye care
How the integration of service improvement technology, and health promotion will allow eye care professionals to overcome current and future challenges. The future of eye care in the UK is at a precipice. Hospital attendances are increasing year on year,...
Cornea, 2-Volume Set: Fundamentals, Diagnosis, Management and Surgery of the Cornea and Conjunctiva (4th Edition)
Originally published in 1997 as a comprehensive set of three volumes on cornea and external eye disease, this two volume edition, published at the end of 2016, offers “a complete multimedia resource, in print, online, eBook and video format”. There...Edible EyeArt in Belfast
Growing up as an early teen in the 90s, I have always loved celebrating art in childhood academic cooking classes, through to cake making for work events. Relating my hobby in fine arts to most recent news, a range of...In conversation with Dr Robert B Nussenblatt
Dr Robert B Nussenblatt is Chief of the Laboratory of Immunology at the National Eye Institute, an eminent ocular immunologist and an expert in clinical research design and conduct. Describe the success or relevance of the SUN project. The Standardization...
Protecting retinal ganglion cells
Glaucoma is considered to be a heterogeneous group of conditions giving retinal ganglion cells (RGC) damage. Lowering intraocular pressure (IOP) reduces the risk of progressive RGC loss in glaucoma. Regeneration of the optic nerve has been shown to restore some...Andy Hill (NuVision Biotherapies) discusses recent AOP update to clinical guidelines
There are currently 600,000 people on the NHS waiting list for ophthalmology treatment, and over 5 million people in the UK currently live with dry eye disease. Here Andy Hill, CEO at NuVision Biotherapies Ltd, discusses a recent update to clinical guidelines and what this means for optometrists, patients, and taxpayers.
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
